ACCC COVID-19 Resource Center & Discussion Group
for Insights on Providing Optimal Patient Care During the Pandemic.
providing a voice for Hawaii's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1996
Meetings & Education
HSCO Patient Education Videos
Medical Aid in Dying
State & Federal Resources
National Professional Organizations
Off-Label Use Literature
Patient Advocacy Organizations
Become a Corporate Member
Industry News Archive
COVID-19 Featured Resources
FDA Approves Azacitidine for AML Continued Treatment
On September 1, 2020 the U.S. Food and Drug Administration (FDA) approved Onureg® (azacitidine) for the continued treatment of patients with acute myeloid leukemia (AML) who achieved first complete remission or complete remission with incomplete blood count recovery following intensive induction chemotherapy and are not able to complete intensive curative therapy.
Bristol Myers Squibb announcement